Shop Research About Compliance Affiliate Free Consultation
Hot

Retatrutide

LY3437943 · GLP-1/GIP/Glucagon Triple Agonist

Triple-agonist GLP-1/GIP/glucagon receptor agonist. Most studied compound in metabolic research.

✓ HPLC Verified ✓ 98%+ HPLC standard ✓ COA Available ✓ Direct Support
📋 Certificate of Analysis — RT5 View third-party COA PDF for 5mg ↗
Retatrutide research peptide vial
Select Size
$125
10-vial kit
+ $40 shipping · Free over $1,000 per tier · US: 2-5 day tracked · Intl: 7-14 day
✓ Added to cart View Cart →
Research Data

What Is Retatrutide?

Retatrutide (LY3437943) is a GIP/GLP-1/glucagon triple receptor co-agonist in Phase 3 clinical investigation. Phase 2 NEJM data (2023) demonstrated up to 24.2% mean body weight reduction at 48 weeks in the highest-dose arm, versus 2.1% with placebo.

Research Context

  • Triple receptor agonism (GLP-1/GIP/glucagon) as a metabolic research model
  • Adiposity reduction and body composition in clinical trial populations
  • Hepatic lipid metabolism and NAFLD pathway modulation
  • Comparative receptor pharmacology vs dual agonists and monoagonists
  • Glucagon receptor contribution to energy expenditure

Storage & Reconstitution

Store lyophilized at -20°C for 12–24 months. Reconstituted in BAC water: refrigerate at 2–8°C, use within 4–6 weeks.

Retatrutide research overview

Retatrutide (LY3437943) is a single peptide that activates three metabolic receptors: GLP-1, GIP and glucagon. The first-generation incretin compounds act on one of these (semaglutide on GLP-1) or two (tirzepatide on GLP-1 and GIP). The added glucagon-receptor activity is the reason retatrutide is studied separately from them: in published research it is associated with higher energy expenditure and hepatic fat oxidation, not only reduced intake.

Receptor-binding work reports the strongest potency at the GIP receptor with balanced activity at the GLP-1 and glucagon receptors, and a 2024 structural study in Cell Discovery describes how one conserved core sequence engages all three receptors. The most cited dataset is the Phase 2 obesity trial published in the New England Journal of Medicine (Jastreboff et al., 2023), which reported a mean 24.2% reduction in body weight at 48 weeks in the highest-dose arm. Eli Lilly's TRIUMPH Phase 3 programme is ongoing, and retatrutide is not approved for any use in any market.

For the full study list, the published safety data and links to each paper, see the Retatrutide research page.

What you receive

Common questions

Is Retatrutide in stock and how fast does it ship?

Retatrutide ships from US stock. US orders go out by UPS with tracking and usually arrive in 2-5 days. International orders are kits only and usually arrive in 7-14 days.

How much is shipping?

$40 per order for kits in the US ($20 when the order is single vials only), $60 for kits shipped internationally, and free on US orders of $1,000 or more.

How can I pay?

Venmo, Zelle, card or Cash App through a secure Square link (5% card fee), or crypto (5% off).

Which size should I choose?

Every size is the same compound and purity; the size only changes how much material is in each vial. Larger sizes cost less per milligram. If you are unsure, message us on Telegram and we will help you compare.

All products sold for research purposes only. Not for human or animal consumption. Must be 21 or older to purchase. By placing an order you confirm compliance with all applicable local laws and regulations.